CpG-STAT3decoy

CpG-STAT3decoy is a bi-functional synthetic oligonucleotide therapeutic that covalently links a STAT3 decoy oligodeoxynucleotide (STAT3dODN) to a Toll-like receptor 9 (TLR9)-stimulating CpG oligodeoxynucleotide to enable selective delivery of a STAT3 transcriptional inhibitor to TLR9-positive myeloid and immune cells, including acute myeloid leukemia (AML) blasts and leukemia stem/progenitor cells.[1][3][5] After rapid, receptor-mediated uptake into TLR9-expressing cells, the conjugate escapes endosomes, where the STAT3 decoy motif binds activated STAT3 dimers in the cytoplasm, sequesters them, and prevents their nuclear translocation and DNA binding, thereby inhibiting STAT3-dependent survival, immune checkpoint, and immunosuppressive gene programs (for example, ARG1) while the CpG component simultaneously provides TLR9 agonism and immune stimulation.[1][3][5] In preclinical AML models, a serum-stabilized form with >60‑hour half-life supports intravenous administration, achieves selective accumulation in leukemic compartments, reduces STAT3 phosphorylation, promotes myeloid differentiation and antigen-presentation gene expression, restores T‑cell proliferation, and mediates direct cytotoxic and CD4/CD8 T cell–dependent eradication of AML cells, supporting its development as an immunomodulatory, STAT3-targeted therapy for hematologic malignancies.[1][2][3][5]

Other names

CpG-STAT3 decoy oligonucleotideCpG-STAT-3 decoy oligonucleotideCpG-STAT 3 decoy oligonucleotideCpG-STAT3 decoyCpG-STAT-3 decoyCpG-STAT 3 decoyCpG-STAT3dODNCpG-STAT-3dODNCpG-STAT 3dODNCpG-STAT3dCpG-STAT-3dCpG-STAT 3d